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Acute mountain sickness was known to the Chinese in ancient times, as they traversed
mountain passes between the Great Headache and Little Headache mountains into present-
day Afghanistan. The Jesuit priest, Father Joseph Acosta, lived in Peru during the sixteenth
century; he described both this syndrome and deaths which occurred in the high Andes. The
incidence of high-altitude illness will rise as previously remote sites become more accessible to
trekkers and skiers. Prevention and treatment are important concerns for those physicians who
wish to advise their more adventuresome patients properly. This article incorporates a selected
review of pertinent investigations, in the English-language literature over the past five years,
into material previously presented at travel symposia for clinicians managing the prophylaxis
and treatment ofacute mountain sickness.
PHYSIOLOGY
There are several excellent references on the subject of acute mountain sickness
(AMS) [1-5]. This field is evolving as trekking, skiing, and rock climbing become
increasingly popular. The various levels of high altitude have been divided into
several zones, which are usefulwhenconsideringthe potential effectsofhigh altitude
on human experience [1,6]. It is quite unusual, or even rare, for significant altitude
illness to occur below the 8,000-foot level. Hence, "high" altitude is arbitrarily
referred to as the zone between 9,000 and 14,000 feet, where acute mountain
sickness is most likely to make its first appearance [1,6]. The usual locations for base
camps and the zone at which serious trekking occurs are at "very high" altitudes,
between 14,000 and 18,000 feet. Acclimatization is required before any attempts are
made to ascend to such levels. Above this zone, and on to Mt. Everest at more than
29,000 feet, are those peaks only approached by serious climbers who become
acclimatized before even reaching such altitudes.
The physiological consequences of high altitude are both considerable and chal-
lenging. Hypoxia is the most obvious one, resulting from decreased barometric
pressure in the external environment. At 18,000 feet, the available oxygen, as
measured by the inspired oxygen tension, is 69 mm Hg (torr), producing an arterial
oxygen tension of44 torr, as compared with 94 torr at sea level. Probably because of
the limits on pulmonary oxygen diffusion capacity at high altitude, there is an
additional fall in arterial P02 at high altitude during exercise. Thisfall does not occur
at sea level. In fact, exercise at sea level is usually accompanied by a slight rise in
arterial P02 [1,6]. In addition, the decrease in ventilation during sleep, or sleep
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hypoventilation, is more marked at high altitude, resulting, at times, in markedly
depressed levels of arterial oxygen saturation. In fact, the major dangers associated
with sleep hypoventilation at high altitude are those due to profound decreases in
arterial oxygen saturation, not respiratory acidosis. Acetazolamide maybe important
in reducing the periodic breathingwhich leads to this exacerbation ofhypoxia during
sleep.
The physiologic changes which predominate at high altitude include respiratory
alkalosis and the slow process ofrenal accommodation, which can require up to two
weeks to complete. Respiratory alkalosis and an initial alkalemia result from
hyperventilation. Thiscondition limits the medullary center sothat it cannot respond
fully to hypoxia until renal excretion of bicarbonate begins to correct the primary
acid-base disturbance and to increase alveolar ventilation. During prolonged hy-
poxia, there is an effective decrease in plasma volume as water moves into hypoxic
cells and interstitial spaces. The rapid increase in erythrocyte 2,3-diphosphoglycer-
ate levels is of uncertain significance, but it may contribute to oxygen unloading in
tissues. Of major importance is the rise in pulmonary arterial pressure associated
with hypoxic pulmonary vasoconstriction. This rise in pulmonary arterial pressure
varies among individuals; it is one of the physiologic responses associated with a
predisposition to high-altitude pulmonary edema, a process which is not cardiac in
origin, butwhich maybe influenced byvasodilators such as nifedipine.
CLINICAL MANIFESTATIONS
Acute mountain sickness is usually manifested by tiredness, headache, anorexia,
nausea, and vomiting [2,5]. By far the most severe and persistent problem is
headache. Sleep patterns are also disturbed, and Cheyne-Stokes respirations maybe
evident; they are characterized by periods ofhyperpnea and apnea with consequent
changes in the arterial P02. Sedation may worsen periods of hypoxia. Auditory and
visual disturbances may appear. Memory becomes impaired, and ataxia may also
occur.
Acute mountain sickness can be prevented by acclimatization in conjunction with
slow ascents and a planned staging process [1,6]. It has been suggested that the rate
of ascent not exceed 1,000 feet per day when climbing above the 10,000-foot level.
Because exercise and hyperventilation increase insensible fluid losses, oral hydration
is important, particularly if the thirst mechanism is blunted at high altitude [1,6].
"Staging" simply means spending several days at an intermediate altitude such as
7,000 feet. One additional dictum is to "sleep low and climb high," so that the
periodic breathing and hypoxia associated with sleeping at high altitude are mini-
mized. Altitude, rate of ascent, level of physical exertion, and prior acclimatization
all influence the incidence and severityofacute mountain sickness.
The consequences of AMS progression are clearly dangerous. With predisposing
factors such as exposure to extreme cold and rapid ascent to high altitude, exertion
and sleeping at such altitudes mayresult inhigh-altitude pulmonary edema. Children
and adolescents are at greatest risk for high-altitude pulmonary edema, and symp-
toms worsen at night. Lack of acclimatization, even in the physically fit, may also
contribute. Recurrent episodes in the same individual are common and appear to be
due to an abnormally high rise in pulmonary arterial resistance [6,14], as a response
to hypoxia.
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PHARMACOLOGICAL INTERVENTION-PREVENTION
Is there anypharmacological intervention which can prevent eitherthe occurrence
of acute mountain sickness or minimize its consequences? Acetazolamide (Dia-
moxT) is a well-known carbonic anhydrase inhibitor, which is used in the treatment
of seizures and glaucoma, but which is a relatively poor diuretic. It does not truly
prevent mountain sickness; it shortens the time of acclimatization by several days.
Acetazolamide increases urinary excretion of bicarbonate, sodium, and potassium
ions. The resulting hyperchloremic metabolic acidosis stimulates respiration, essen-
tially producing, in one day, what would require about five days during the normal
process of acclimatization. Its mechanism of action also appears to include ventila-
tory stimulation at high altitude and a decrease in resting hypoxemia, nocturnal
restlessness, apnea, and oxygen desaturation at high altitude. Adams and Johnson
have produced experimental data in rats regarding the respiratory effects of inhibit-
ing carbonic anhydrase in brain tissue by infusion of acetazolamide directly into the
cistema magna [7]. The inhibition ofcarbonic anhydrase in medullary tissue appears
to increase the ventilatory response to rebreathing CO2. The baseline steady-state
respiration during room airbreathingwas, however, not affected bythe experimental
doses ofacetazolamide that were used.
The appropriate dose ofacetazolamide for prevention ofacute mountain sickness
is not entirely clear. The recommended dose has been 250 mg by mouth every eight
to 12 hours for about five days, with the subject completing therapy upon reaching
the highest altitude. It has been suggested, however, that the inhibitory effects of
acetazolamide on carbonic anhydrase activity in tissues may be excessive at this
dosage level, and some suggest using a lower dose, such as 250 mg/day [8].
Acetazolamide should not be taken with triazolam (Halcion) or barbiturates, as it
may potentiate their effects on the central nervous system, resulting in an inadequate
ventilatory response [9]. Paresthesias and occasional cramping of the hands or feet
should be expected, along with occasional gastrointestional upset, somnolence, or
transient myopia. Patients with sulfonamide drug sensitivity or renal disease should
not utilize acetazolamide.
Miller and Miller have confirmed previous observations of altered taste (dysgeu-
sia) less than two hours after taking 250 mg of acetazolamide for prevention of
mountain sickness [10]. Altered taste for carbonated and non-carbonated beverages
and food occurred in association with paresthesias of lips, tongue, and lower
extremities. Patients require a warning regarding these potential side effects. The
paresthesias, in particular, may be especially intolerable forpatients who arevisually
impaired and rely on touch.
Dexamethasone is a potent glucocorticoid. It was first used to prevent acute
mountain sickness largely upon the assumption that brain edema contributed to its
pathogenesis. Unfortunately, corticosteroid side effects ofeuphoria, glucose intoler-
ance, mania, potential gastrointestional hemorrhage, and steroid withdrawal must
also be considered. Dexamethasone has been used in doses of two to four mg every
six hours, beginning on the day of ascent, continuing for three days at higher
elevations, and tapering the dose over the subsequent five days. In one study,
acetazolamide (250 mg, twice each day) and dexamethasone (4 mg, four times daily)
were more effective than either agent alone for the prevention of acute mountain
sickness [11].
Ellsworth et al. have added to theirprevious data on the efficacyofdexamethasone
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forprevention ofacute mountain sickness [12]. Arapid ascent ofMount Rainierwas
performed twice by 18 climbers in a randomized, double-blind, concurrent, placebo-
controlled trial, comparing acetazolamide (250 mg), dexamethasone (4 mg), and
placebo everyeighthours asprophylaxisforacutemountain sickness. An environmen-
tal symptoms questionnaire and clinical interview demonstrated greater reduction in
the incidence and severity ofacute mountain sicknesswith dexamethasone thanwith
acetazolamide or placebo. At the summit, 10 percent ofsubjects taking dexametha-
sone were "sick" by clinical interview criteria. In contrast, 75 percent of those
receiving acetazolamide were ill in a similar evaluation. This studywaswell designed
and, despite a small number of subjects, it suggests that a role for dexamethasone is
emerging for those who cannot tolerate acetazolamide, or for whom it is simply
ineffective. The authors also suggest using dexamethasone for those undergoing a
forced rapid ascent to high altitude over a short time span when a guaranteed retreat
route is available; however, potential corticosteroid side effects will continue to
dictate limited use ofdexamethasone prophylaxis.
TREATMENT OF ACUTE MOUNTAIN SICKNESS
Therapy ofacute mountain sickness is truly immediate descent from high altitude.
The role for supplementary oxygen does not include itsbeing used as a substitute for
an immediate descent from high elevations. Acetaminophen or non-steroidal anti-
inflammatory agents can be used to control headaches. Retinal hemorrhages can
appear at altitudes around 14,000 feet; they are common above 18,000feet, although
they resorb in days. Macularhemorrhages can affectvision andtheoreticallycouldbe
exacerbated by aspirin's effects on platelet function.
Grissom et al. [13] have used low-dose acetazolamide'to treat acute mountain
sickness in climbers on Denali (Mt. McKinley) [14]. Using two doses of 250 mg at
zero and eight hours, with assessment ofstatus at 24 hours, they demonstrated some
benefit in the treatment of AMS in six subjects, compared to placebo-treated
controls. Parameters measured included symptomatology, changes in alveolar to
arterial oxygen pressure difference and arterial P02. The authorsconclude, fromthis
small initial study, that acetazolamide is effective for the treatment of established
cases of acute mountain sickness and its use is associated with improved pulmonary
gas exchange. Dexamethasone has also been used to treat acute mountain sickness.
It is clearly useful in some cases, particularly if evacuation to a lower altitude is
delayed. For those clinicianswho have longthought that acetazolamide offered relief
of symptoms to those with acute mountain sickness, it represents a useful first
alternative to corticosteroids.
Naeije and Melot recently reported a case of high-altitude pulmonary edema in a
40-year-old man, who had been a healthy subject for pulmonary hemodynamics
studies six years previously [15]. He had had a normal pulmonary arterial hypoxic
pressor response at that time. The authors speculate that, in this patient, use ofboth
acetazolamide and dexamethasone so diminished his non-respiratory symptoms that
he delayed his descent. Neither agent has ever been shown to improve high-altitude
pulmonary edema.
Rest, supplemental 02, and rapid descent are the first modes oftherapy for acute
mountain sickness. Nifedipine, a calcium channel blocker, is still considered an
experimental agent [16]. Bartsch et al. have shown that the prophylactic administra-
tion of nifedipine not only prevents high-altitude pulmonary edema in susceptible
subjects but also lowers the symptom score for acute mountain sickness. Side effects
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ofnifedipine include nausea,vomiting, headache, hypotension, and fatigue. It should
not be utilized simply to prevent symptoms ofacute mountain sickness.
The lightweight portable hyperbaric chamber, or Gamow bag, may be the most
important recent advance in therapy. Dr. Igor Gamow developed an airtight,
zippered, nylon bag which is both light and portable. The patient with acute
mountain sickness is zipped into the bag and air is pumped in continuously with a
foot pump to a pressure of 100 torr or two pounds per square inch (psi), simulating
an altitude of 8,400 feet [6]. An air flow rate of30 L/minute is produced with 10-15
pumps per minute, while the bag is vented through a 2 psi gauge pop-off valve in
order to keep a constant bag pressure and air exchange in the bag. When rapid
evacuation or descent is not possible, the positive-pressure bag provides almost
immediate reliefofsymptoms [17].
When central nervous system manifestations of high-altitude illness progress to
cerebral edema, ataxia, confusion, and somnolence, high-altitude encephalopathy
has ensued. This syndrome can produce abnormal reflexes and focal neurological
deficits with associated papilledema and retinal hemorrhages. Treatment, with the
addition of dexamethasone, is the same as for high-altitude pulmonary edema. In
each case, descent is absolutely critical. With appropriate preventive measures, much
can be done to prevent acute mountain sickness. When it does occur despite such
measures, it should not be ignored. To do so is to risk more life-threatening events,
such as pulmonary and central nervous system complications. When in doubt, begin
your descent immediately.
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